Matches in Nanopublications for { ?s ?p "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- _4 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.
- _2 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.
- _2 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.
- _2 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.
- _2 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.
- _4 value "Epidermal growth factor receptor (EGFR)?specific tyrosine kinase inhibitors (TKI) gefitinib and erlotinib have been developed as therapeutic agents for non?small cell lung cancer (NSCLC) treatment (1, 2, 3)." provenance.